hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06299644, orgStudyIdInfo id: 2023P003282, briefTitle: Endoscopic Sleeve Gastroplasty Technique Comparison for Weight Loss, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2025-05-01, primaryCompletionDateStruct date: 2026-07-01, completionDateStruct date: 2026-12-31, studyFirstPostDateStruct date: 2024-03-08, lastUpdatePostDateStruct date: 2024-03-08, sponsorCollaboratorsModule leadSponsor name: Brigham and Women's Hospital, class: OTHER, collaborators name: Endo Tools Therapeutics S.A., descriptionModule briefSummary: The Investigators propose suture plication placement at the distal gastric body drives a significant portion of weight loss in endoscopic sleeve and sutures only need to be placed in the distal gastric body. Therefore, in this pilot study, the investigators aim to compare "belt" with "belt and suspenders" plication pattern using the Endomina system to determine percent total weight loss., conditionsModule conditions: Obesity, conditions: Obesity, Morbid, conditions: Metabolic Disease, conditions: Weight, Body, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 10, type: ESTIMATED, armsInterventionsModule interventions name: Endoscopic Sleeve Gastroplasty - Belt and Suspenders, interventions name: Endoscopic Sleeve Gastroplasty - Belt, outcomesModule primaryOutcomes measure: Percent TWL (%TWL), primaryOutcomes measure: Adverse Events, secondaryOutcomes measure: Gastric Emptying, secondaryOutcomes measure: Number of participants with improvement in fasting glucose, secondaryOutcomes measure: Number of participants with improvement in Hemoglobin A1c (HgA1c %), secondaryOutcomes measure: Improvement in fasting lipids profile, secondaryOutcomes measure: Number of participants with a change in ghrelin hormone values, secondaryOutcomes measure: Obesity-related comorbidities - hypertension, secondaryOutcomes measure: Obesity-related comorbidities - change in hypertension concomitant medications, secondaryOutcomes measure: Obesity-related comorbidities - change in pre-diabetes/diabetes concomitant medications, secondaryOutcomes measure: Obesity-related comorbidities - pre-diabetes/diabetes, secondaryOutcomes measure: Obesity-related comorbidities - gastroesophageal reflux (GERD), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Brigham and Women's Hospital, city: Boston, state: Massachusetts, zip: 02115, country: United States, geoPoint lat: 42.35843, lon: -71.05977, hasResults: False
protocolSection identificationModule nctId: NCT06299631, orgStudyIdInfo id: RECHMPL23_0187, briefTitle: Endoscopic Relapse Risks Evaluation After Ileocolic Resection for Crohn's Disease, acronym: RIC-1, statusModule overallStatus: COMPLETED, startDateStruct date: 2015-01, primaryCompletionDateStruct date: 2023-06, completionDateStruct date: 2023-12, studyFirstPostDateStruct date: 2024-03-08, lastUpdatePostDateStruct date: 2024-03-08, sponsorCollaboratorsModule leadSponsor name: University Hospital, Montpellier, class: OTHER, collaborators name: Carémeau University Hospital, Nîmes, descriptionModule briefSummary: Aim of the study:To evaluate risk factors of endoscopic relapse after ileocolic resection in a cohort of Crohn's disease patients treated with anti-TNF agents.Methods:From 2014 to 2022, all consecutive patients who underwent ileocolic resection for Crohn's disease treated with anti-TNF agents in two referral tertiary center were prospectively collected.Considering exclusion criteria, data from 114 patients were analyzed. The cohort was separated into 2 groups according to study period.Short and long-term outcomes were compared between the two groups.Primary outcome:Endoscopic recurrence (defined as \> i2 lesions according to Rutgeerts classification) 6 months after surgery, conditionsModule conditions: Crohn's Disease, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: PROSPECTIVE, enrollmentInfo count: 133, type: ACTUAL, armsInterventionsModule interventions name: Ileocolic resection, outcomesModule primaryOutcomes measure: Endoscopic recurrence rate, secondaryOutcomes measure: Resection margins, secondaryOutcomes measure: Length of resected specimen, secondaryOutcomes measure: Duration of surgery, secondaryOutcomes measure: Intra-operative blood loss, secondaryOutcomes measure: Postoperative morbidity rate, secondaryOutcomes measure: Mortality rate, secondaryOutcomes measure: Myenteric plexitis, secondaryOutcomes measure: Number of inflammatory cells in myenteric plexuses, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 99 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Montpellier University Hospital, city: Montpellier, zip: 34295, country: France, geoPoint lat: 43.61092, lon: 3.87723, hasResults: False
protocolSection identificationModule nctId: NCT06299618, orgStudyIdInfo id: ENIGMA-I, briefTitle: Environmental Influence on Mental Illness Via Modifications of Genomes and Metabolomes in Adolescents With Autism, acronym: ENIGMA-I, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2025-05, completionDateStruct date: 2025-12, studyFirstPostDateStruct date: 2024-03-08, lastUpdatePostDateStruct date: 2024-03-08, sponsorCollaboratorsModule leadSponsor name: University College Cork, class: OTHER, collaborators name: University of Southampton, collaborators name: Carol Davila University of Medicine and Pharmacy, collaborators name: Microlink PC UK LTE, collaborators name: Engineering Ingegneria Informatica SpA, collaborators name: MEDEA SRL, collaborators name: ORTHOKEY ITALIA SRL, descriptionModule briefSummary: The aim of the study is to enrich the understanding of the physiological mechanisms that predispose autistic adolescents to mental illness. It will inform a possible pathway and biomarker handprint of mental illness severity and prognosis to formulate a neurobiologically informed personalization strategy that could be applied for selecting appropriate Evidence Based Intervention (EBI) for treating an adolescent formally diagnosed with Autism., conditionsModule conditions: Autism, conditions: Autism Spectrum Disorder, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 400, type: ESTIMATED, outcomesModule primaryOutcomes measure: Symptoms of anxiety, primaryOutcomes measure: Symptoms of anxiety, primaryOutcomes measure: Symptoms of depression, primaryOutcomes measure: Symptoms of depression, otherOutcomes measure: Attention-Deficit/Hyperactivity, otherOutcomes measure: Sleep disturbance, otherOutcomes measure: Physical Activity, otherOutcomes measure: Symptoms of Mental Health Disorders, otherOutcomes measure: Cognitive Assessment, otherOutcomes measure: Nutritional Assessment, otherOutcomes measure: Heart Rate, otherOutcomes measure: Respiratory Rate, otherOutcomes measure: Genotype, otherOutcomes measure: DNA Methylation, otherOutcomes measure: Hormone Levels, otherOutcomes measure: Metabolomic Profile, eligibilityModule sex: ALL, minimumAge: 11 Years, maximumAge: 15 Years, stdAges: CHILD, contactsLocationsModule locations facility: University College Cork, city: Cork, country: Ireland, contacts name: Deirdre Murray, PhD, role: CONTACT, email: enigma@ucc.ie, contacts name: Jean Conway, Masters, role: CONTACT, email: ethereal@ucc.ie, geoPoint lat: 51.89797, lon: -8.47061, locations facility: University of Medicine and Pharmacy Carol Davila Bucharest, city: Bucharest, country: Romania, geoPoint lat: 44.43225, lon: 26.10626, locations facility: University of Southampton, city: Southampton, country: United Kingdom, contacts name: Samuele Cortese, MD, role: CONTACT, contacts name: Koushik Maharatna, PhD, role: CONTACT, email: km3@ecs.soton.ac.uk, geoPoint lat: 50.90395, lon: -1.40428, hasResults: False
protocolSection identificationModule nctId: NCT06299605, orgStudyIdInfo id: SHARE2401, briefTitle: Triple Versus Quadruple Therapy for the Eradication of Helicobacter Pylori, acronym: SHARE2401, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2024-10, completionDateStruct date: 2024-11, studyFirstPostDateStruct date: 2024-03-08, lastUpdatePostDateStruct date: 2024-03-08, sponsorCollaboratorsModule leadSponsor name: Shandong University, class: OTHER, collaborators name: Binzhou Maternal and Child Health Hospital, collaborators name: Zibo Maternal and Child Health Hospital, collaborators name: Zaozhuang Municipal Hospital, collaborators name: Linyi Yizhou Hospital, collaborators name: Feicheng Municipal People's Hospital, descriptionModule briefSummary: The study aimed to compare the efficacy and safety of 7-day and 14-day vonoprazan-amoxicillin-tetracycline triple therapy with 14-day vonoprazan-amoxicillin-tetracycline-bismuth quadruple therapy for the eradication of Helicobacter pylori. Subjects were randomized to receive the intervention and were reviewed by 13C-urea breath test after 6 weeks. The eradication rates, adverse reaction rates and patient adherence were calculated., conditionsModule conditions: Helicobacter Pylori Infection, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 375, type: ESTIMATED, armsInterventionsModule interventions name: Vonoprazan-Amoxicillin-Tetracycline-Bismuth quadruple regimen for 14 days, interventions name: Vonoprazan-Amoxicillin-Tetracycline triple regimen for 14 days, interventions name: Vonoprazan-Amoxicillin-Tetracycline triple regimen for 7 days, outcomesModule primaryOutcomes measure: Eradication rate, secondaryOutcomes measure: Rate of adverse reactions, secondaryOutcomes measure: Patient compliance, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06299592, orgStudyIdInfo id: 2023-1626, secondaryIdInfos id: 1RF1AG082215-01, type: NIH, link: https://reporter.nih.gov/quickSearch/1RF1AG082215-01, secondaryIdInfos id: A538900, type: OTHER, domain: UW- Madison, secondaryIdInfos id: SMPH/PSYCHIATRY/PSYCHIATRY, type: OTHER, domain: UW- Madison, secondaryIdInfos id: Protocol Version 10/15/2023, type: OTHER, domain: UW- Madison, briefTitle: Comparison of Microglial Activation in Severe Asthma and Healthy Controls, acronym: MAIA-SC, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-06, primaryCompletionDateStruct date: 2028-08, completionDateStruct date: 2028-08, studyFirstPostDateStruct date: 2024-03-08, lastUpdatePostDateStruct date: 2024-03-27, sponsorCollaboratorsModule leadSponsor name: University of Wisconsin, Madison, class: OTHER, collaborators name: National Institute on Aging (NIA), descriptionModule briefSummary: The goal of this clinical trial is to learn about how asthma influences brain function. The main questions it aims to answer are:* How airway inflammation in asthma affects the brain; and,* Whether airway inflammation in asthma is related to symptoms of depression and anxietyOver the course of 3 visits, participants will:* Complete questionnaires* Complete computer tasks* Undergo allergy skin test and breathing tests* Give two blood samples* Give a sputum sample* Complete brain imaging scansResearchers will compare results between participants with asthma, and participants who do not have asthma., conditionsModule conditions: Asthma, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: PROSPECTIVE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: PET/MRI using [18F]FEPPA tracer, outcomesModule primaryOutcomes measure: Binding of [18F]-FEPPA, secondaryOutcomes measure: How activated microglia correspond to immune biomarkers in lung and blood, secondaryOutcomes measure: Relationship between activated microglia and cognitive function, secondaryOutcomes measure: Relationship between activated microglia and psychological symptoms, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Center for Healthy Minds, status: RECRUITING, city: Madison, state: Wisconsin, zip: 53703, country: United States, contacts name: Janelle Grogan, role: CONTACT, phone: 608-263-0524, email: jegrogan@medicine.wisc.edu, contacts name: Melissa Rosenkranz, PhD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 43.07305, lon: -89.40123, hasResults: False
protocolSection identificationModule nctId: NCT06299579, orgStudyIdInfo id: WG-GD11-III-01, briefTitle: GD-11 for Injection in the Treatment of Acute Ischemic Stroke, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-29, primaryCompletionDateStruct date: 2025-02-22, completionDateStruct date: 2025-12-31, studyFirstPostDateStruct date: 2024-03-08, lastUpdatePostDateStruct date: 2024-03-15, sponsorCollaboratorsModule leadSponsor name: Beijing Tiantan Hospital, class: OTHER, collaborators name: Jiangsu Wangao Pharmaceutical Co. ltd, descriptionModule briefSummary: Phase III Clinical Trial of GD-11 for Injection in the Treatment of Acute Ischemic Stroke - A Multi-Center, Randomized, Double-Blind, Parallel, Placebo-Controlled Phase III Clinical Study with the primary objective of evaluation of the efficacy and safety of GD-11 for injection in the treatment of acute ischemic stroke patients within 48 hours. The subject has a clinical diagnosis of acute ischemic stroke, within 48 hours from stroke onset to start of study treatment, with a National Institutes of Health Stroke Scale (NIHSS) between 6 and 20, had a total score of upper and lower limbs on motor deficits ≥ 2. The primary outcome is the proportion of subjects with mRS score ≤ 1 at 90 days after treatment., conditionsModule conditions: Acute Ischemic Stroke, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: This trial is designed as a multicenter, randomized, double-blind, placebo-parallel controlled trial using a multicenter, randomized, double-blind, placebo-parallel controlled trial design. Subjects are randomly assigned in a 1:1 ratio and random number tables are generated using SAS（Statistics Analysis System）software., primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, enrollmentInfo count: 980, type: ESTIMATED, armsInterventionsModule interventions name: GD-11 for injection test group, interventions name: Placebo control group, outcomesModule primaryOutcomes measure: Proportion of subjects with mRS score ≤1 on 90th day of treatment, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 81 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Beijing Tiantan Hospital Capital Medical University Beijing, status: NOT_YET_RECRUITING, city: Beijing, state: Beijing, zip: 100000, country: China, contacts name: Yongjun Wang, role: CONTACT, email: yongjunwang111@aliyun.com, contacts name: Yongjun Wang, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 39.9075, lon: 116.39723, locations facility: Linfen Central Hospital, status: RECRUITING, city: Shangxi, state: Linfen City, zip: 041099, country: China, contacts name: hongguo Dai, role: CONTACT, email: daihongguo3199@163.com, hasResults: False
protocolSection identificationModule nctId: NCT06299527, orgStudyIdInfo id: 01032024, briefTitle: Telerehabilitation in Patients With Fibromyalgia, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-05-27, primaryCompletionDateStruct date: 2023-11-15, completionDateStruct date: 2024-01-27, studyFirstPostDateStruct date: 2024-03-08, lastUpdatePostDateStruct date: 2024-03-13, sponsorCollaboratorsModule leadSponsor name: Marmara University, class: OTHER, descriptionModule briefSummary: Sixty-six FMS patients received the same exercise program for 8 weeks and divided, synchronous (n: 33), asynchronous (n: 33). Pain (Visual analog Scale, VAS), functional limitations and disabilities (Revised Fibromyalgia Impact Questionnaire, FEA), health-related quality of life (HRQol; Short Form-12, SF 12), catastrophizing (pain catastrophizing scale, PCS), anxiety and depression (Hospital Anxiety and Depression Scale, HAD), functional capacity (6-minute walking test, 6MWT), muscle strength (Arm curl test) joint position sense (Laser Cursor Assisted Angle Repetition Test, LI-RATT) were assessed at baseline, mid-treatment (week 4), end of treatment (week 8), and eight weeks after treatment (week 16)., conditionsModule conditions: Fibromyalgia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 66, type: ACTUAL, armsInterventionsModule interventions name: Exercise Program, outcomesModule primaryOutcomes measure: Visual Analog Scale, secondaryOutcomes measure: Revised Fibromyalgia Impact Questionnaire, secondaryOutcomes measure: Pain Catastrophizing Scale, secondaryOutcomes measure: Hospital Anxiety and Depression Scale, secondaryOutcomes measure: 6 Minute Walk Test, secondaryOutcomes measure: Arm Curl Test, secondaryOutcomes measure: Laser Cursor Assisted Angle Repetition Test (LI-RATT), secondaryOutcomes measure: Short Form - 12, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Faculty of Health Sciences, city: Istanbul, state: Maltepe, zip: 1464185881, country: Turkey, geoPoint lat: 41.01384, lon: 28.94966, hasResults: False
protocolSection identificationModule nctId: NCT06299501, orgStudyIdInfo id: LS 2015-1199 and 2017-24, briefTitle: How Can Child Health Services Identify and Respond to Family Violence, statusModule overallStatus: COMPLETED, startDateStruct date: 2017-08-23, primaryCompletionDateStruct date: 2019-08-31, completionDateStruct date: 2019-08-31, studyFirstPostDateStruct date: 2024-03-07, lastUpdatePostDateStruct date: 2024-03-08, sponsorCollaboratorsModule leadSponsor name: Karolinska Institutet, class: OTHER, collaborators name: Jane and Dan Olsson Foundation for Scientific Purposes, collaborators name: Region Stockholm, descriptionModule briefSummary: Family violence has severe impacts on children's health and development. The Child Health Services (CHS) in Sweden reaches almost 100% of families with young children and provides a unique setting to facilitate identification of family violence. This study is a three-armed randomized controlled trial (RCT) conducted to assess the effectiveness of different approaches to identify family violence within CHS. Two different approaches are tested and compared to treatment as usual; 1) information about family violence at home visit when child is newborn, and questions posed to all mothers at the 6-8-week visit; 2) information about family violence at home visit when child is newborn, and questions posed to mothers on evidence based indication. Nurses who are randomized into any of the two intervention arms receive training and supervision. The outcomes of the study are related to knowledge, attitudes, and practices around identification and support in case of family violence and number of identified cases of family violence., conditionsModule conditions: Family Violence, conditions: Domestic Violence, conditions: Intimate-partner Violence, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Three-armed study, two intervention groups and one control group, primaryPurpose: HEALTH_SERVICES_RESEARCH, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 85, type: ACTUAL, armsInterventionsModule interventions name: Routine questions, interventions name: Questions on evidence based indication, interventions name: Treatment as usual, outcomesModule primaryOutcomes measure: Knowledge, attitudes and practices, secondaryOutcomes measure: Number of cases of family violence, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Central Child Health Care (Centrala barnhälsovården), city: Stockholm, country: Sweden, geoPoint lat: 59.33258, lon: 18.0649, hasResults: False
protocolSection identificationModule nctId: NCT06299475, orgStudyIdInfo id: 2023-06755-01, briefTitle: Structured Online Contraceptive Counseling (LOWE Trial) at Emergency Contraception (EC) Pharmacy Provision LOWE+EC=LOWEC, acronym: LOWEC, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2025-07, completionDateStruct date: 2026-09, studyFirstPostDateStruct date: 2024-03-07, lastUpdatePostDateStruct date: 2024-03-07, sponsorCollaboratorsModule leadSponsor name: Karolinska Institutet, class: OTHER, collaborators name: the Swedish Pharmacy Association, descriptionModule briefSummary: To increase sexual and reproductive health and rights through the improvement of contraceptive counseling and easy access to service and, thus, women's use of effective contraceptives after purchase of an emergency contraceptive pill (ECP)., conditionsModule conditions: Contraception, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, interventionModelDescription: A cluster randomized crossover trial, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: NONE, enrollmentInfo count: 600, type: ESTIMATED, armsInterventionsModule interventions name: Online counseling and invitation, outcomesModule primaryOutcomes measure: Use of effective contraception, secondaryOutcomes measure: Contraceptive use, secondaryOutcomes measure: Incidence of pregnancy and abortion, secondaryOutcomes measure: Satisfaction with the intervention, secondaryOutcomes measure: Contraceptive use, pregnancy, abortion and satisfaction in vulnerable groups, secondaryOutcomes measure: Process evaluation, eligibilityModule sex: FEMALE, minimumAge: 15 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False